ATAI stock should trade near the $6.75 cash component plus some value for the CVRs, with the spread reflecting deal risk (stockholder vote, antitrust, timing). Monitor the proxy filing and HSR review timeline. CVR milestones are binary catalysts: VLS-01 Phase 3 start (4yr), BPL-003 US approval/DEA rescheduling (5yr), VLS-01 US approval/DEA rescheduling (7yr). Lilly's resources increase probability of success but CVRs are contingent and non-transferable.
Price Chart
Executive Summary
Eli Lilly (LLY) has agreed to acquire AtaiBeckley (ATAI) for $6.75 per share in cash plus up to $2.50 per share in contingent value rights (CVRs) tied to clinical and regulatory milestones for BPL-003 and VLS-01. The upfront cash consideration represents approximately $2.8 billion in aggregate equity value, a ~40% premium to the 30-day VWAP. The transaction is expected to close in Q3 2026, subject to stockholder approval, HSR clearance, and other customary conditions.
Key Financial Metrics
Key Facts
- Lilly to acquire ATAI for $6.75/share cash + up to $2.50/share in CVRs ($1.00 on VLS-01 Phase 3 start, $0.50 on BPL-003 US approval/DEA rescheduling, $1.00 on VLS-01 US approval/DEA rescheduling)
- Upfront cash equity value ~$2.8B; CVR potential additional ~$1.0B
- ~40% premium to ATAI's 30-day volume-weighted average price as of July 15, 2026
- Transaction expected to close in Q3 2026; not subject to financing condition
- Voting agreements cover ~15% of outstanding shares (Apeiron Investment Group, directors, and officers)
- BPL-003 (intranasal 5-MeO-DMT) has Breakthrough Therapy Designation for TRD; Phase 3 activities initiated
- VLS-01 (buccal DMT) in Phase 2b; EMP-01 (oral (R)-MDMA) in Phase 2
- Termination fee of $104.3M payable by ATAI under specified circumstances
Financial Impact
ATAI shareholders receive $6.75/share cash at close (~$2.8B aggregate) plus CVRs worth up to $2.50/share (~$1.0B aggregate) contingent on milestones; premium of ~40% to 30-day VWAP
Risk Factors
- Stockholder approval may not be obtained; ~15% locked up via voting agreements but remaining shareholders could vote no
- HSR or other antitrust/FDI clearances could delay or block the deal
- CVR milestones may not be achieved (clinical failure, regulatory denial, DEA scheduling issues), resulting in zero additional payments
- Go-shop provision allows ATAI to consider superior proposals, though a $104.3M termination fee applies
- Integration risk post-close; Lilly may deprioritize programs
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (ATAI) — Batch item 1 | 0001140361-26-028605 |
| Document: 0001140361-26-028605-index-headers.html | 0001140361-26-028604 |
| Document: 0001140361-26-028605-index.html | 0001140361-26-028605 |
| Document: 0001140361-26-028605.txt | 0001140361-26-028604 |
| DEFA14A Filing (ATAI) — Batch item 5 | 0001140361-26-028605 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 25-NSE | $7.30 awaiting T+20 | awaiting T+20 | — | — |
Aug 10, 2026 7w ago | DEFM14A | $7.25 $7.28 | ▲ +0.41% | ▲ +1.33% | — |
Aug 9, 2026 7w ago | Institutional Cluster | $7.25 $7.28 | ▲ +0.41% | ▲ +1.33% | — |
Jul 16, 2026 11w ago | DEFA14A / 8-K | $7.15 $7.25 | ▲ +1.40% | ▼ −2.22% | — |
Jul 7, 2026 12w ago | 144 | $5.17 $7.22 | ▲ +39.65% | ▲ +36.38% | — |
Jul 6, 2026 12w ago | Press Release | $4.96 $7.18 | ▲ +44.76% | ▲ +45.32% | — |
Jun 26, 2026 14w ago | 144 | $5.36 $7.18 | ▲ +33.96% | ▲ +34.23% | — |
Jun 25, 2026 14w ago | 144 | $5.29 $7.17 | ▲ +35.54% | ▲ +34.28% | — |
Jun 3, 2026 17w ago | 8-K | $4.53 $5.19 | ▲ +14.57% | ▲ +15.57% | — |
May 12, 2026 20w ago | Press Release | $4.15 $3.78 | ▼ −8.92% | ▼ −7.19% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access